STOCK TITAN
  1. Home
  2. News
  3. QLGN

Qualigen Therapeutics Inc - QLGN STOCK NEWS

Welcome to our dedicated news page for Qualigen Therapeutics (Ticker: QLGN), a resource for investors and traders seeking the latest updates and insights on Qualigen Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Qualigen Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Qualigen Therapeutics's position in the market.

News
Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting
Rhea-AI Summary
Qualigen Therapeutics, Inc. presents preclinical data on Novel Direct Pan-RAS Inhibitors at the AACR Annual Meeting 2024, showing potential for broad-based cancer treatment. The compounds target various RAS mutations with minimal toxicity, suggesting promising therapeutic applications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.74%
Tags
none
-
News
Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting
Rhea-AI Summary
Qualigen Therapeutics, Inc. presents early clinical data on its novel anti-cancer drug QN-302 at AACR Annual Meeting 2024. Encouraging results show no DLTs or SAEs in pancreatic cancer patients, with some showing stable disease. Dose escalation ongoing with positive patient outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.56%
Tags
none
-
News
Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023
Rhea-AI Summary
Qualigen Therapeutics, Inc. (Nasdaq: QLGN) announced the initiation of dosing for three patients in the first cohort of the Phase 1 clinical trial of QN-302 for the treatment of advanced or metastatic solid tumors. The company shared scientific data on QN-302 at the AACR Special Conference, highlighting potential biomarkers and gene targets. Additionally, the company partnered with TD2 for the Phase 1 clinical development of QN-302. Qualigen also presented a poster on the Pan-RAS inhibitor platform at the AACR Special Conference, which showed promising results. The company completed the divestiture of its FastPack® diagnostics business to focus on its therapeutics pipeline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors
Rhea-AI Summary
Qualigen Therapeutics, Inc. (Nasdaq: QLGN) announces the dosing of the first patient in the Phase 1a clinical trial for QN-302, a potential first-in-class, investigational G-Quadruplex-selective transcription inhibitor designed for the treatment of advanced or metastatic solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.29%
Tags
clinical trial
-
News
Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer
Rhea-AI Summary
Qualigen Therapeutics presents preclinical data on Pan-RAS compounds at AACR Special Conference in Breast Cancer Research
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.73%
Tags
none
-
News
Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023
Rhea-AI Summary
Qualigen Therapeutics presents posters on QN-302 at AACR Special Conference on Pancreatic Cancer. QN-302's Investigational New Drug application cleared by FDA. QN-302 on track to enter the clinic this year. Studies show potential biomarkers and down-regulated genes associated with QN-302 in PDAC. QN-302 shows nanomolar potency and G4 stability. Pancreatic Cancer affects 95,389 people in the US. AACR conference highlights advancements in pancreatic cancer research.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.96%
Tags
none
News
Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid Tumors
Rhea-AI Summary
Qualigen Therapeutics partners with Translational Drug Development for Phase 1 clinical development of lead drug candidate QN-302. QN-302 is a small molecule G-Quadruplex-selective transcription inhibitor for the treatment of advanced or metastatic solid tumors. Qualigen received FDA clearance to initiate the Phase 1 clinical trial. The partnership aims to bring QN-302 to patients with high unmet medical need.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.74%
Tags
partnership clinical trial
-
News
Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023
Rhea-AI Summary
Qualigen Therapeutics, Inc. has received US FDA clearance to initiate Phase 1 clinical trial of QN-302 for the treatment of advanced or metastatic solid tumors. The company also divested its FastPack® diagnostics business for approximately $5 million in an all-cash transaction. Revenues from product sales increased by 14% compared to the same period last year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.1%
Tags
earnings
-
News
Qualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors
Rhea-AI Summary
Qualigen Therapeutics has received Investigational New Drug (IND) clearance from the FDA for QN-302, a potential best-in-class small molecule G-Quadruplex (G4)-selective transcription inhibitor. The company plans to initiate a Phase 1 clinical trial in the second half of 2023 for patients with advanced or metastatic solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
News
Qualigen Therapeutics Divests FastPack® Diagnostics Business
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock QLGN logo
Qualigen Therapeutics Inc

Nasdaq:QLGN

QLGN Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

QLGN Stock Data

2.09M
6.27M
9.26%
2.61%
1.27%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Los Angeles